An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.
Investigational Treatment Acquiring Traction Online
The experimental drug, which is still in clinical trials, is being advertised by social media influencers for its supposed weight-reducing effects. Followers are encouraged to message these accounts directly for source information, while also receiving discount codes.
Thriving Commerce on Social Networks
Separately, a robust trade exists on Telegram, where groups with thousands of participants share comparison photos, injection guides and assertions of next-day UK delivery. Sellers market the substance there before directing customers to WhatsApp for transactions.
Understanding The Experimental Drug
This medication is an experimental injection developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Early trials suggest it could help patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.
Healthcare Experts Express Worries
Nevertheless, physicians and pharmacists have warned that the distribution of what is still an unapproved drug in the United Kingdom is a cause for concern and could result in individuals administering substances of unknown origin.
Some professionals said the demand for the experimental drug could be linked to the increasing price of licensed slimming products such as Mounjaro.
Regulatory Position and Enforcement
Marketing retatrutide on social media or Telegram is illegal in the UK, as it is an unapproved medication that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.
Several content creators attempt to sidestep the rules by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted substance, but promotion and distribution can still breach pharmaceutical, advertising, and consumer regulations, risking fines, legal action or imprisonment.
Platform Reaction and Material Elimination
According to the social media company, the platform has removed violative material and banned related keywords and query recommendations. The organization stated it was committed to maintaining the platform safe and investing in enhancing compliance measures.
Online Marketplace Activities
Investigations also found groups with up to 9,000 members marketing the experimental drug using the platform's integrated search feature, which functions like a public directory. Typing “retatrutide” instantly displays groups with numerous of members, filled with photos of weight loss, glowing testimonials and detailed guides for preparing or administering at home.
Within minutes of joining one community, a seller posted contact information, where the majority of transactions occur. The vendor provided an guidebook and guaranteed shipping within 48 hours. When asked whether the product was genuine, one vendor said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or past usage.
Item Information and Costs
Inside these groups, messages show dark colored packages with Royal Mail labels, claiming to include fresh supplies. One communication stated: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at residence with sterile water, or ready-to-use injectors usually sold at 160 pounds for 20mg. When asked how much time a pen should last, sellers give conflicting answers varying between a several days to “depends on your body”.
Platform Oversight and Safety Actions
A spokesperson for the messaging service said it actively moderated dangerous content on its service including material that encouraged the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“People are administering materials they cannot confirm. Although the science behind this drug is sound, these online products may not include what they advertise,” said Jason Murphy, the head of pharmaceutical services at Chemist4U.
A medical professional of Asda Online Doctor linked the increase in interest to current cost increases for approved weight-loss medications such as Mounjaro. “With costs increasing, individuals are using online platforms. But fake treatments are highly risky. You cannot know what’s inside or whether the environment they were produced in was clean,” she said.
Her staff has already encountered individuals harmed by self-injection from unverified sources. “We understand the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These substances could be impure or improperly measured.”
Manufacturer Position
A spokesperson from the pharmaceutical company said the substance was in phase 3 research studies and had not been reviewed or approved by any government authority globally. “Consequently at this time no one can sell [it] for human use,” they said, noting that any product “falsely representing itself as a Lilly experimental product not yet authorized … may expose patients to possibly significant medical dangers”.
